GlaxoSmithKline | GSK - Selling And Administration Expenses



GlaxoSmithKline reported GBP2.14B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Alcon AG USD 870M 57M Jun/2025
Almirall EUR 91.3M 55.52M Mar/2025
Amgen USD 1.69B 4M Jun/2025
argenx SE USD 321.35M 45.11M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Bayer EUR 3.55B 162M Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Fresenius EUR 740M 97M Jun/2025
Fresenius Medical Care EUR 792M 41M Jun/2025
Galapagos EUR 30.67M 13.12M Jun/2025
Genmab DKK 144M 18M Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Glaxosmithkline GBP 2.09B 609M Jun/2025
GRIFOLS EUR 282.76M 41.9M Jun/2025
Hikma Pharmaceutical USD 288M 8M Dec/2024
Merck EUR 1.48B 9M Jun/2025
Merck USD 2.63B 104M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Novo Nordisk 18.85B 2.74B Jun/2025
Orion EUR 96.7M 12.4M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Philips EUR 1.24B 9M Jun/2025
Recordati EUR 186.98M 5.59M Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sanofi EUR 2.63B 408M Jun/2025
Smith & Nephew USD 1.42B 77.8M Jun/2025
UCB EUR 1.29B 221M Dec/2024